You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Claims for Patent: 10,357,514

✉ Email this page to a colleague

Summary for Patent: 10,357,514

Title:	Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
Abstract:	The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
Inventor(s):	Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
Assignee:	Novartis AG , Mayo Foundation for Medical Education and Research , University of Pennsylvania Penn , Novartis Institutes for Biomedical Research Inc
Application Number:	US14/680,860

Details for Patent 10,357,514

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646	August 30, 2017	10,357,514	2035-04-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,357,514

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
South Africa	201605657	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	2015157252	⤷ Get Started Free
United States of America	2019388471	⤷ Get Started Free
United States of America	2015283178	⤷ Get Started Free
Taiwan	I753848	⤷ Get Started Free
Taiwan	201600092	⤷ Get Started Free
Slovenia	3888674	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.